Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes

American Journal of Hypertension

Volumn 29, Issue 9, 2016, Pages 1055-1062

  Redon, Josep ^a,b   Pichler, Gernot ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cardiovascular risk; Central blood pressure; Diabetes; Fixeddose combination; Hypertension; Missed dose

Indexed keywords

AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS PERINDOPRIL; ANTIDIABETIC AGENT; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; URIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; PERINDOPRIL; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; ARTICLE; AUGMENTATION INDEX; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POST HOC ANALYSIS; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; MIDDLE AGED;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PERINDOPRIL; PULSE WAVE ANALYSIS; TETRAZOLES;

EID: 84991290286     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpw033     Document Type: Article

References (45)

1. Trudeau L. Central blood pressure as an index of antihypertensive control: determinants and potential value. Can J Cardiol 2014; 30:S23-S28.
2. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 2012; 308:875-881.
3. Narayan O, Casan J, Szarski M, Dart AM, Meredith IT, Cameron JD. Estimation of central aortic blood pressure: a systematic meta-analysis of available techniques. J Hypertens 2014; 32:1727-1740.
4. Davies JM, Bailey MA, Griffin KJ, Scott DJ. Pulse wave velocity and the non-invasive methods used to assess it: Complior, SphygmoCor, Arteriograph and Vicorder. Vascular 2012; 20:342-349.
5. Pichler G, Martinez F, Vicente A, Solaz E, Calaforra O, Redon J. Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment. J Hypertens 2015; 9:1868-1875.
6. Mitchell GF, Hwang S-J, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121:505-511.
7. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation 2001; 103:987-992.
8. Aksnes TA, Skårn SN, Kjeldsen SE. Treatment of hypertension in diabetes: what is the best therapeutic option? Expert Rev Cardiovasc Ther 2012; 10:727-734.
9. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
10. Karalliedde J, Smith A, De Angelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51:1617-1623.
11. Gismondi RA, Oigman W, Bedirian R, Pozzobon CR, Ladeira MC, Neves MF. Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Renin Angiotensin Aldosterone Syst 2015; 16:967-974.
12. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S. Brachial pressure-independent reduction in carotid stiffness after longterm angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48:80-86.
13. Spoelstra-de Man AME, van Ittersum FJ, Schram MT, Kamp O, van Dijk RA, Ijzerman RG, Twisk JW, Brouwer CB, Stehouwer CD. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. J Hum Hypertens 2006; 20:599-611.
14. Johansen NB, Charles M, Vistisen D, Rasmussen SS, Wiinberg N, Borch-Johnsen K, Lauritzen T, Sandbæk A, Witte DR. Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screendetected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2012; 35:2207-2214.
15. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ 2011; 14:576-583.
16. Redon J, Pichler G; Missed Dose Study Group. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens 2016; 34:359-367.
17. Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressurelowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 2008; 30:108-120.
18. Lacourcière Y, Asmar R; Candesartan/Losartan Study Investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999; 12:1181-1187.
19. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-353.
20. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P; on behalf of The Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J 2014; 35:3122-3133.
21. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31:1865-1871.
22. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2013; 75:79-92.
23. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009; 15:272-289.
24. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118-123.
25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
26. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
27. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011; 25:346-353.
28. Volpe M, de la Sierra A, Ammentorp B, Laeis P. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther 2014; 31:561-574.
29. Barrios V, Brommer P, Haag U, Calderón A, Escobar C. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009; 29:427-439.
30. Kereiakes DJ, Chrysant SG, Izzo JL, Littlejohn T, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol 2012; 11:134.
31. Zhang Y, Ly C, Yannoutsos A, Agnoletti D, Mourad JJ, Safar ME, Blacher J. Effect of a fixed combination of perindopril and amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: the AVANT'AGE study. J Am Soc Hypertens 2013; 7:163-169.
32. Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens 2015; 9:266-274.
33. Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther 2013; 30:1086-1099.
34. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, Le Fevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 2014; 311:507-520.
35. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 2001; 19:S21-S32.
36. Lees KR, Hughes DM, McNeill CA, Reid JL. Pharmacokinetics of perindopril: therapeutic consequences. Clin Exp Hypertens A 1989; 11(Suppl 2):499-506.
37. Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 2006; 113:657-663.
38. Franklin SS. Beyond blood pressure: arterial stiffness as a new biomarker of cardiovascular disease. J Am Soc Hypertens 2008; 2:140-151.
39. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23:551-556.
40. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002; 20:2423-2428.
41. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26:609-614.
42. Lacolley P, Safar ME, Regnault V, Frohlich ED. Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. Am J Physiol Heart Circ Physiol 2009; 297:H1567-H1575.
43. Metoki H, Obara T, Asayama K, Satoh M, Hosaka M, Elnagar N, Miyawaki Y, Kojima I, Ohkubo T, Imai Y; Japan-Home versus Office Blood Pressure Measurement Evaluation-Augmentation Index Study Investigators. Differential effects of angiotensin II receptor blocker and losartan/hydrochlorothiazide combination on central blood pressure and augmentation index. Clin Exp Hypertens 2015; 37:294-302.
44. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
45. Cheng HM, Lang D, Tufanaru C, Pearson A. Measurement accuracy of non-invasively obtained central blood pressure by applanation tonometry: a systematic review and meta-analysis. Int J Cardiol 2013; 167:1867-1876.